PTHrP (parathyroid hormone-related protein) is crucial for normal cartilage development and long bone growth and acts to delay chondrocyte hypertrophy and terminal differentiation in the growth plate. After growth plate closure adult HACs (human articular chondrocytes) still produce PTHrP , suggesting a possible role for this factor in the permanent articular cartilage. However, the expression regulation and function of PTHrP in the permanent articular cartilage is unknown. Human articular cartilage is an avascular tissue and functions in a hypoxic environment. The resident chondrocytes have adapted to hypoxia and use it to drive their tissue-specific functions. In the present study, we explored directly in normal articular chondrocytes isolated from a range of human donors the effect of hypoxia on PTHrP expression and whether PTHrP can regulate the expression of the permanent articular chondrocyte phenotype. We show that in HACs PTHrP is up-regulated by hypoxia in a HIF (hypoxia-inducible factor)-1α and HIF-2α-dependent manner. Using recombinant PTHrP , siRNA-mediated depletion of endogenous PTHrP and by blocking signalling through its receptor [PTHR1 (PTHrP receptor 1)], we show that hypoxia-induced PTHrP is a positive regulator of the key cartilage transcription factor SOX9 [SRY (sex determining region on the Y chromosome)-box 9], leading to increased COL2A1 (collagen type II, α1) expression. Our findings thus identify PTHrP as a potential factor for cartilage repair therapies through its ability to promote the differentiated HAC phenotype.
INTRODUCTION
Chondrocytes are the exclusive cell type of cartilage tissue. They alone produce and maintain a highly specialized extracellular matrix, providing the cartilage in the articulating joints with its particular biomechanical features -the ability to withstand both compressive and tensional forces allowing near friction-free movement in the joint and protection of the underlying bones [1] .
Chondrocyte differentiation, cartilage development and the expression of cartilage-specific matrix genes are all controlled by SOX9 [SRY (sex determining region on the Y chromosome)-box 9], a transcription factor of the SRY family that plays the role of master regulator of the chondrocyte phenotype [2, 3] . Decreased
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SOX9 expression leads to loss of the differentiated phenotype in culture [4, 5] , and is one of the major limitations of the current cell-based therapies for cartilage repair. In addition, deceased SOX9 levels are implicated in phenotypic changes occurring in joint disease, namely osteoarthritis [6] .
Articular cartilage is an avascular tissue, and therefore (at least in larger animals where diffusion distances are significant), it functions in a hypoxic environment [7] [8] [9] [10] . In all metazoan cell types, the HIFs (hypoxia-inducible factors) are key transcription factors that co-ordinate and regulate the hypoxic response [11] . HACs (human articular chondrocytes) have adapted to this chronic (physiological) hypoxia and actually use hypoxia (via the HIFs) to drive their tissue-specific functions [5, 12, 13] .
We have shown previously that hypoxia helps promote expression of the differentiated HAC phenotype predominantly through HIF-2α-mediated up-regulation of SOX9, which in turn drives the expression of the main cartilage-specific extracellular matrix genes [14] .
PTHrP (parathyroid hormone-related protein) was first identified as the factor causing hypercalcaemia in cancer patients. It is produced by many different cell types in normal physiological conditions and mediates a wide range of actions from vasodilation to mammary gland development [15] . PTHrP acts through the same receptor as PTH (parathyroid hormone), but unlike PTH, it appears to act locally to regulate tissue function [15] . PTHrP has been demonstrated to be a crucial regulator of the growth plate chondrocytes, and hence of skeletal development and of bone growth [16, 17] . In this context, it is produced by periarticular chondrocytes and perichondral cells, and acts by allowing the continued proliferation of the columnar chondrocytes and suppressing their terminal differentiation into postmitotic hypertrophic chondrocytes [16, 18] . Adult articular chondrocytes also express and secrete PTHrP [19, 20] , suggesting that this autocrine/paracrine factor can potentially play a physiological role in the regulation of cartilage function throughout life. However, the function of PTHrP in the permanent articular cartilage is unclear.
A study by Fischer et al. [19] has shown that HACs secrete PTHrP and that in co-cultures a factor secreted by HACs was able to inhibit the hypertrophic differentiation of human mesenchymal stem cells undergoing chondrogenesis. Although direct evidence was not provided, the authors argued this factor was PTHrP since the treatment of differentiating stem cells with recombinant PTHrP (in the absence of HACs) had similar effects. Moreover, it has recently been shown in cancer and endothelial cells that PTHrP expression is positively regulated by hypoxia through HIF-2α [21] .
These observations prompted us to explore in detail the regulation and possible physiological function of PTHrP in articular chondrocytes isolated from human donors. Using recombinant PTHrP, siRNA-mediated interference of PTHrP and by blocking of PTH/PTHR1 (PTHrP receptor 1) signalling using specific antibodies, we report that hypoxia-inducible PTHrP is a positive regulator of cartilage master regulator SOX9 in HACs, which drives tissue-specific matrix synthesis. The present study thus establishes a new physiological role for PTHrP in healthy HACs, and identifies PTHrP as a potential therapeutic target for cartilage repair.
MATERIALS AND METHODS

HACs isolation and culture
Normal healthy articular cartilage was obtained from the femoral condyle and tibial plateau of a total of 15 patients, with an average age of 33 years (five female, ten male; age range, 8-66 years) amputated for osteosarcoma or soft tissue sarcoma after informed patient consent and following local ethics committee guidelines. Samples were only taken from patients where the joint space was unaffected as described previously [22] . Articular cartilage was dissected on the same day as surgery and diced into cubes (of 1-2 mm 2 width) before overnight digestion in 1.5 mg/ml of Collagenase 2 (Worthington) in DMEM (Dulbecco's modified Eagle's medium) containing 10 % FBS (fetal bovine serum) (Biosera), with incubation on a shaker (approximately 50 rev./min) at 37
• C. Freshly isolated cells were seeded at a density of 8×10 3 /cm 2 (in DMEM containing 10 % FBS and antibiotics). The medium was changed twice a week and cultures were passaged upon reaching confluency (approximately 7 days). For subsequent subculture, cells were seeded at 5×10 3 cells/cm 2 . Expansion of cells was performed in normoxia (20 % O 2 ) and P1-P3 (first to third passage) HACs were used in experiments.
siRNA transfections
HACs were seeded at 5×10 3 cells/cm 2 in six-cm-diameter dishes and incubated at 37
• C in 20% O 2 /5 % CO 2 until 50 % confluent (typically after 1 day). Lipofectamine TM 2000 (Invitrogen) was used to transfect the cells with siRNA at a final concentration of 10 nM in serum-free Opti-MEM I (Invitrogen). Validated siRNA targeting HIF-1α, HIF-2α, SOX9 and PTHrP were used (Silencer Select siRNA; Ambion). As a negative control, a noninterfering siRNA was transfected in parallel (Silencer Negative Control siRNA; Ambion). At 4 h after transfection, the medium was removed and replaced with DMEM containing 10 % FBS pre-equilibrated at the appropriate O 2 tension (20 % or 1 %). Cells were subsequently incubated in each O 2 tension for 2-3 days.
RNA isolation, RT (reverse transcription) and real-time PCR
HACs were washed with ice-cold PBS and total RNA was extracted using the TriZOL ® Reagent (Invitrogen). Digestion of contaminating genomic DNA was performed with DNA-free DNase Treatment (Ambion). First-strand cDNA was generated using an RT kit with random primers (High Capacity cDNA Reverse Transcription kit; Applied Biosystems) from 1 μg of total RNA. Newly synthesized cDNA was diluted 5-fold in DNase-free water and 5 % of this cDNA was then used in each real-time PCR assay, using a 7900 Real-Time PCR System (Applied Biosystems) with SYBR Green PCR master mix (Applied Biosystems). The standard curve method was used to calculate relative mRNA levels for each transcript examined and RPLP0 (ribosomal protein, large P0) was used as reference gene to normalize the data, as it was shown not to be regulated by hypoxia in our system [23] . Specific primers used for SYBR green RT-PCR were as follows: PTHrP: forward primer 5 -CCGCCGCCTCAAAAGAG-3 , reverse primer (Rv)-5 -GCCGTAAATCTTGGATGGACTT-3 ; PTHR1: forward primer, 5 -TGGCGAGGTACAAGCTGAGA-3 and reverse primer, 5 -GCGTGCCTTTCGCTTGA-3 ; ZFP521 (zinc finger protein 521): forward primer, 5 -TCCCTCAAAGACCCCAACTG-3 and reverse primer, 5 -TTC-TTACAATCTAGTGCCTCTCCATCT-3 ; CCND1 (cyclin D1): forward primer, 5 -CACGCGCAGACCTTCGT-3 and reverse primer, Rv-5 -ATGGAGGGCGGATTGGAA-3 ; COL10A1 (collagen type X, α-1): forward primer, 5 -CACGCAGAA-TCCATCTGAGAATAT-3 and reverse primer, 5 -GTTCAGC-GTAAAACACTCCATGAA-3 ; PHD1 (prolyl hydroxylase 1):
PTHrP expression in HACs is induced by hypoxia in a HIF-1α-and HIF-2α-dependent manner (A) Western blotting showing efficient depletion of both HIF-α isoforms in HACs. α-tubulin was used as a loading control.
(B-D) Real-time PCR analysis of SOX9, PTHrP and PHD1 gene expression in siRNA-transfected HACs. PHD1 was used as a negative control as it is not hypoxia-inducible. Cells were transfected with 10 nM control (non-interfering) siRNA (denoted as 'C'), or with 10 nM siRNA directed against HIF-1α and HIF-2α (singly, or in combination). Cultures were lysed after 3 days in normoxia (20 % O 2 ) or hypoxia (1 % O 2 ). Expression data were normalized using reference gene RPLP0. Bars represent the means from seven independent experiments (i.e. HACs from seven different human donors). * P < 0.05 and * * * P < 0.001 (one-way ANOVA with Dunnett's multiple comparison post-test, and paired Student's t test for control 20 % against 1 % O 2 comparison). ns, not significant.
forward primer, 5 -TTGACCGGTTGCTCATTTTCT-3 and reverse primer, 5 -TGGCGTACCTGGTGGCATA-3 . SOX9, COL2A1 (collagen type II, α-1), RUNX2 (Runt-related transcription factor 2) and RPLP0 primers were as detailed previously [22] .
Protein extraction and immunoblotting
HACs were washed with PBS and lysed in RIPA (radio immune-precipitation assay) buffer [100 mM Tris/HCl, pH 7.4, 150 mM NaCl, 20 mM sodium fluoride, 2 mM EDTA, 0.2 mM 2-glycerophosphate, 1 mM sodium vanadate, 2 % (w/v) deoxycholate, 10 mM Na 4 P 2 O 7 , 0.5 % SDS and 1 % (v/v) Nonidet P40] containing a protease inhibitor cocktail (Complete TM Mini; Roche). Cells were sonicated and cleared by centrifugation (14 000 g for 10 min at 4
• C), and the whole-cell lysate supernatant was collected. Proteins were resolved by SDS/PAGE, transferred on to Protran nitrocellulose membranes, and immunoblotted under standard conditions with primary antibodies as follows: anti-SOX9 (1:1000 dilution; AB5535, Chemicon), anti-HIF-1α (1:250 dilution; clone-54, BD Transduction Laboratories), anti-HIF-2α (1:250 dilution; Sc-13596, Santa Cruz Biotechnology), anti-α-tubulin monoclonal antibody (1:4000 dilution; Sigma) and anti-COL2A1 monoclonal antibody (1:1000 dilution; MAB8887, Chemicon). HRP (horseradish peroxidase)-conjugated anti-(mouse IgG) or anti-(rabbit IgG) secondary antibodies and a chemiluminescence detection kit were purchased from Amersham Biosciences.
PTH/PTHR1 blocking experiments
HACs were seeded at 5×10 3 cells/cm 2 in six-cm-diameter dishes in DMEM containing 10 % FBS under normoxia (20 % O 2 ) . After one day cultures were switched to DMEM/10 % FBS containing 10 mg/ml an anti-PTH/PTHrP receptor antibody (mouse monoclonal antibody, isotype IgG1κ raised against the extracellular domain of the type I PTH/PTHrP receptor; clone 3D1.1, Millipore). As a control, 10 mg/ml of matched isotype mouse IgG1κ . Expression data were normalized using RPLP0. Bars represent the mean from four to five independent experiments (i.e. HACs from four to five different human donors). No significant differences were found in expression of chondrocyte hypertrophy markers RUNX2 and COL10A1, or of CCND1. However, known PTHrP target gene ZFP521 was significantly up-regulated by hypoxia in a PTHrP-dependent manner. * * * P < 0.001 (one-way ANOVA with Dunnett's Multiple comparison post-test, and paired Student's t test for control 20 % against 1 % O 2 comparison). ns, not significant (Dako) was used in parallel cultures. After 1 day with blocking antibody (or control IgG1κ) cultures were transferred to hypoxic conditions (1 % O 2 ) for a further 48 h without changing the medium. HACs were then washed with PBS, and lysed with the appropriate buffer and subjected to either Western blotting or real-time PCR analysis.
Treatment of HACs with exogenous PTHrP
Cells were seeded at 4×10 3 cells/cm 2 in six-cm-diameter dishes in DMEM containing 10 % FBS under normoxia (20 % O 2 ). After 1 day, cultures were switched to DMEM/10 % FBS supplemented with 100 nM human recombinant PTHrP (Peprotech) and 0.1 % BSA as the carrier protein. As a control, cells were cultured in DMEM/10 % FBS with 0.1 % BSA. HACs were cultured under normoxia (20 % O 2 ) or hypoxia (1 % O 2 ) in this medium for a total of 6 days (with a medium change after 3 days). Cultures were finally lysed and subjected to Western blotting or to realtime PCR analysis.
Statistical analysis
Results were analysed using a paired Student's t test, or one-way ANOVA with Dunnett's Multiple Comparison post-hoc test. The software GraphPad Prism 4 (GraphPad Software) was used to perform statistical analysis. Results are expressed as means + − S.E.M. P values < 0.05 were considered statistically significant.
RESULTS
PTHrP expression in HACs is induced by hypoxia in a HIF-1α-and HIF-2α-dependent manner
To investigate the role of the PTHrP in HACs, we performed experiments using cells isolated from healthy human articular cartilage from a range of donors. In order to assess the HIF dependence of genes in hypoxia, RNAi-mediated depletion of each HIF-α isoform in HACs was performed ( Figure 1A ). In agreement with previous observations [14] hypoxia significantly up-regulated expression of master chondrocyte regulator, transcription factor SOX9, largely through HIF-2α ( Figure 1B) . The expression of PTHrP, like SOX9, was significantly increased by hypoxia ( Figure 1C ). However, this hypoxic induction did not show HIF-α isoform specificity as it was abolished by depletion of either HIF-1α or HIF-2α ( Figure 1C) . As a form of control, PHD1, a gene not regulated by hypoxia [23] , was assessed ( Figure 1D ), and as expected its expression was unchanged by hypoxia or HIF depletion. Gene expression was measured by real-time PCR analysis and data were normalized using reference gene RPLP0. Bars represent the mean from four to five independent experiments (i.e. HACs from four to five different human donors). * P < 0.05 and * * P < 0.01 (paired Student's t test). ns, not significant.
PTHrP does not regulate hypertrophic marker expression in HACs
In developing bones and the growth plate, PTHrP has been shown to inhibit chondrocyte hypertrophy [16] . Chondrocytes in the permanent articular cartilage are characterized by the fact that they do not undergo hypertrophy, thus we investigated whether a function of PTHrP in HACs might be to suppress hypertrophy. If this were the case depletion of endogenous PTHrP should increase expression of hypertrophy markers. RNAi-mediated depletion of PTHrP was typically about 90 % efficient (results not shown). Expression of hypertrophy markers RUNX2 and COLXA1 was unaffected by depletion of PTHrP in HACs (Figures 2A and 2B) . In fact, the expression levels of these genes were very low compared with SOX9 and COL2A1 (results not shown). Similarly, CCND1 expression was not regulated by PTHrP ( Figure 2C ). ZFP521 has been shown to be directly targeted by PTHrP and appears to mediate some of its effects [24] . We observed hypoxic induction of ZFP521, which was prevented by PTHrP depletion ( Figure 2D ) indicating that ZFP521 is responsive to endogenous PTHrP in HACs under hypoxic conditions. Thus these experiments indicate that endogenous PTHrP may be functional in HACs but does not appear to influence genes controlling chondrocyte hypertrophy.
PTHrP expression is not regulated by SOX9 in HACs
SOX9 is a potent transcriptional activator of cartilage-specific genes, the most functionally important being COL2A1 [2] . In addition, it has been reported that SOX9 may positively regulate Pthrp gene expression in mouse rib chondrocytes [25] . We observed that in HACs under hypoxic conditions, depletion of SOX9 by transfection of specific siRNAs dramatically decreased the expression of its classic target gene COL2A1, but had no effect on PTHrP gene expression (Figure 3 ). Thus the hypoxiainducible PTHrP gene is not under the transcriptional control of SOX9 in HACs.
Exogenous PTHrP and PTH/PTHR1 signalling in HACs modulate the expression of SOX9 in hypoxia
In order to explore whether PTHrP can promote expression of the differentiated HAC phenotype, we treated monolayer-expanded HACs with exogenous (recombinant) PTHrP. As can be seen in Figure 4 (A) (top panel), SOX9 protein levels in third-passage HACs were enhanced by exogenous PTHrP treatment in hypoxic conditions. Since chondrocyte subculture leads to a gradual reduction in the expression of the differentiated HAC markers [14] , we repeated the experiment in first passage HACs (Figure 4A , lower panel). As expected basal SOX9 levels are greater in the less-passaged cells, nevertheless, both hypoxic induction and PTHrP induction of SOX9 are similarly observed in both cultures.
To further investigate this PTHrP-mediated response, we blocked signalling through the PTHrP receptor using a specific blocking antibody (a monoclonal antibody raised against the extracellular domain of the PTHR1) and noted decreased SOX9 protein levels ( Figure 4B ). These latter experiments were performed in hypoxia in the absence of exogenous PTHrP indicating that functional signalling through the PTHrP receptor is required for the enhanced SOX9 expression observed in hypoxia in endogenous conditions. SOX9 and COL2A1 gene expression were also increased by exogenous PTHrP treatment in hypoxia, and, interestingly, expression of the PTHR1 was increased by hypoxia alone and further increased by exogenous PTHrP treatment in hypoxia (Supplementary Figure S1 at http://www.clinsci.org/ cs/125/cs1250461add.htm). Thus this increased receptor expression in hypoxia may enhance sensitivity to exogenous PTHrP in these conditions. Similar to SOX9, type II collagen protein levels in HAC cultures were enhanced by exogenous PTHrP treatment in hypoxic conditions (Supplementary Figure S1D) .
Depletion of endogenous PTHrP impairs hypoxic induction of the differentiated HAC phenotype
To further uncover the role of endogenous PTHrP in HACs, we selectively depleted PTHrP by transfecting gene-specific siRNAs in cultures subjected to hypoxia. Depletion of PTHrP strikingly reduced (but did not completely abolish) the hypoxic induction (3-day treatment) of SOX9 and its target COL2A1 at the protein level ( Figure 5A ). SOX9 was also directly depleted using gene-specific siRNA (last lane on blots). As expected SOX9-depleted HACs have even lower levels of COL2A1 protein than PTHrP-depleted cultures. The specificity of the type II collagen antibody was previously confirmed by siRNA experiments in our laboratory (results not shown) and in the present study by the fact that depletion of SOX9 (which specifically controls COL2A1 expression) greatly decreases the type II collagen band detected. Two different siRNAs were used to deplete endogenous PTHrP transcripts, and both were found to be very effective (Figure 5B ). Similar to results at the protein level, gene expression of both SOX9 and its transcriptional target COL2A1 was significantly reduced by the depletion of PTHrP in hypoxic conditions ( Figures 5C and 5D ). Thus PTHrP is induced by hypoxia and positively regulates the differentiated HAC phenotype through up-regulation of SOX9 at the mRNA and protein levels.
DISCUSSION
In the skeletal system PTHrP has been established as an essential regulator of the maturation of growth plate chondrocytes, and in this manner it plays a critical role in endochondral bone growth postnatally [16] [17] [18] . In humans, after the growth plate closure upon reaching skeletal maturity, the role of PTHrP in the articular cartilage, if any, remains unknown. Interestingly, however, it has been shown that HACs continue to express and secrete PTHrP [19] , suggesting that it can potentially play a role in the regulation of articular cartilage function. In the present study, we provide evidence that in HACs PTHrP is positively regulated by hypoxia (a physiological condition in human articular Depletion of endogenous PTHrP impairs hypoxic induction of SOX9 and COL2A1 in HACs (A) Protein levels of SOX9 and its main transcriptional target COL2A1 are both reduced by PTHrP depletion in hypoxia (3-day treatment). SOX9 was also directly depleted using gene-specific siRNA (last lane of blots). (B-D) Real-time PCR gene expression analysis of PTHrP , SOX9 and COL2A1 in PTHrP-depleted cultures. Cells were depleted of PTHrP by transfection of two different gene-specific siRNAs (shown separately), before culture in hypoxia (1 % O 2 ) for 2-3 days. As a control, a non-interfering siRNA (denoted as 'C'), was transfected in parallel cultures. Expression data were normalized using reference gene RPLP0. Bars represent the mean from four independent experiments (i.e. HACs from four different human donors). * P < 0.05, * * P < 0.01 and * * * P < 0.001 (paired Student's t test).
cartilage), and that it promotes, in an autocrine manner through PTH/PTHrP receptor signalling, the differentiated HAC phenotype through up-regulation of transcription factor SOX9, which drives cartilage matrix synthesis (summarized in Figure 6 ). Human articular cartilage is an avascular tissue, and the chondrocytes, which are the only cell-type resident in cartilage, develop and function in a hypoxic environment [5, 12, 26] . We have demonstrated previously that the differentiated HAC phenotype is promoted by hypoxia through HIF-2α-mediated up-regulation of the master chondrogenic transcription factor SOX9 [14] . In the present paper, we report that PTHrP expression is up-regulated by hypoxia in HACs in a HIF-1α-and HIF-2α-dependent manner. Clustered consensus-binding sequences for HIFs are present in the human PTHrP gene, and further analysis will establish if HIFs directly target PTHrP in HACs.
In addition to hypoxia, mechanical stimulation is another key physiological condition to which cartilage is exposed in the articulating joints. Work by Chen et al. [20] has shown that PTHrP expression is regulated by mechanical loading in mouse articular cartilage, and it will be of interest to investigate the effects of mechanical load on PTHrP expression in HACs. Interestingly, unlike in the growth plate, PTHrP expression can be uncoupled from IHH (Indian hedgehog) signalling in murine articular cartilage [20] , and the present study is in agreement with this finding as there was no IHH source (pre-hypertrophic/hypertrophic chondrocytes) in the HAC experiments. It appears that in the permanent articular cartilage PTHrP expression can be regulated independently of IHH under the control of physiological signals, such as hypoxia and mechanical loading. The degree to which the IHH/PTHrP axis is active and functional in human articular cartilage remains to be seen.
PTHrP abundance is notoriously low, making measurements of this secreted protein difficult. Indeed, it is normally only detected in pathological conditions, and, even in tumours associated with hypercalcaemia of malignancy caused by abnormally high levels of PTHrP, a 62000-fold enrichment was needed to identify the causative factor [27] . Nevertheless, in high cell density pellet cultures of HACs secreted PTHrP protein was detectable [19] . In the present study, the low cell density of HAC monolayer cultures (needed for cell transfections) prevented such detection at the protein level even in pooled, concentrated samples. However, generation of the PTHrP-lacZ mouse has indicated that the PTHrP mRNA expression pattern accurately reflects the protein's distribution and function [28] . Furthermore, in the present study, using three different approaches -recombinant PTHrP, siRNA-mediated depletion of endogenous PTHrP and by blocking PTH/PTHrP receptor signalling using specific antibodies -we show that in HACs hypoxia-induced PTHrP is a positive regulator of SOX9, which subsequently drives cartilage-specific matrix gene expression. These results, to the best of our knowledge, provide for the first time evidence that PTHrP, acting in an autocrine manner in HACs, promotes expression of the differentiated phenotype. PTHrP appears to play the role of a tuner of the differentiated HAC phenotype since depletion of PTHrP impairs, but does not completely abolish hypoxic induction of SOX9 and COL2A1. The role PTHrP in postnatal articular cartilage in mice was investigated using control sequences of GDF5 to drive deletion of PTHrP in the mid-region of mouse articular cartilage [29] . Although there were no obvious differences in unchallenged mice, knockout mice were more susceptible to experimentally induced degenerative changes. These findings are in line with our own in that they demonstrate a chondroprotective effect of articular chondrocyte-derived PTHrP.
Most of the actions of PTHrP are thought to be mediated through the PTH/PTHrP1 and there is a similarly severe skeletal phenotype between PTHrP-null and PTHR1-null mice [16] . In addition, mice expressing a constitutively active form of the PTH/PTHrP receptor specifically in cartilage can prevent the neonatal death of PTHrP-null mice and correct many of their defects [30] . The positive regulation of SOX9 by PTHrP observed in the present study in HACs also seems to be mediated through type I PTH/PTHrP receptor activation since blocking this receptor reduced SOX9 levels in hypoxia in a very similar manner to depletion of endogenous PTHrP. In addition, exogenous PTHrP increased SOX9 levels. In murine growth plate chondrocytes (but not articular), PTHrP has been shown to activate SOX9 transcriptional activity by phosphorylation of SOX9 without changes in SOX9 levels [31] . In contrast, in the present study, PTHrP positively regulates SOX9 at the mRNA and protein level. How PTHrP increases SOX9 mRNA levels remains to be elucidated. In the mouse growth plate ZFP521, a zinc finger transcriptional co-regulator, was found to mediate some of the effects of the PTHrP in controlling the transition from prehypertrophic to hypertrophic chondrocytes [24] . We found that in HACs the expression of ZFP521 is induced by hypoxia (similarly to PTHrP), and furthermore, depletion of PTHrP in hypoxia prevented the hypoxic induction of ZFP521. Further studies will explore whether ZFP521 is a downstream effector of PTHrP in the regulation of SOX9 in HACs.
In the present study, of necessity, HACs were passaged prior to use to create sufficient cell numbers for experiments. Although subculture of chondrocytes under standard (normoxic) conditions leads to a partial loss of the differentiated phenotype [32] , we and others have previously shown that the differentiated phenotype is promoted (in both primary and passaged chondrocytes) by culture in hypoxia [4, 5, [12] [13] [14] 23, 33] . In the present study, both hypoxic induction of SOX9 and SOX9 induction by exogenous PTHrP was similarly observed in third passage and first passage HAC cultures; although, as expected, basal SOX9 levels were reduced in the third passage cells. Interestingly, since HACs are routinely sub-cultured in cell-based cartilage repair therapies [34] , PTHrP treatment could be used to aid re-expression of the differentiated phenotype prior to re-implantation of the cells. In the present study, recombinant PTHrP was used at 100 nM. Although this concentration is likely to be supraphysiological, it was chosen since prior studies investigating chondrogenic differentiation have used the same [35] or greater (micromolar) concentrations [36] . In addition, three independent approaches gave consistent results. That is, adding exogenous PTHrP increases, while blocking endogenous PTHrP (through blocking antibody and RNAi experiments) decreases, SOX9 levels, thus providing convincing evidence that PTHrP positively regulates SOX9 in HACs.
More generally, administration of PTHrP may represent a promising therapeutic treatment for cartilage repair. Animal studies provide further evidence in support of this. A decrease in PTH/PTHrP receptor expression in articular chondrocytes was observed in surgically induced osteoarthritis in rabbits [37] . Interestingly, this correlates with phenotypic changes, specifically decreased expression of SOX9, reported in human osteoarthritic cartilage [38] . Another recent study in rabbits showed that activation of PTH/PTHrP signalling enhanced repair of full-thickness articular cartilage defects [39] . Our results in HACs suggest that PTHrP could mediate such in vivo effects through up-regulation of SOX9 that drives cartilage matrix synthesis. Before clinical application, however, appropriate large animal models are needed to test the therapeutic potential of PTHrP for articular cartilage repair.
r PTHrP is crucial for cartilage development and long bone growth. After growth plate closure upon reaching skeletal maturity HACs (the exclusive cell type of articular cartilage) continue to express and secrete PTHrP, suggesting it can potentially play a role in the regulation of articular cartilage function. Our aim was to uncover any such role.
r Hypoxia is a physiological condition in the avascular human articular cartilage and we report that PTHrP is up-regulated by hypoxia in HACs in a HIF-dependent manner. We show that hypoxia-induced PTHrP promotes the differentiated articular chondrocyte phenotype through up-regulation of key cartilage transcription factor SOX9.
r Our findings establish a functional role for PTHrP in HACs, and identify PTHrP as a potential target for cartilage repair therapies through its ability to promote the differentiated HAC phenotype.
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